U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07302919) titled 'Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma' on Dec. 11.
Brief Summary: IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine would significantly improve the success rate of TACE treatment.
Study Start Date: Jan. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Hepato Cellular Carcinoma (HCC)
Intervention:
COMBINATION_PRODUCT: DEB-DoxNic-TACE
TACE (transarterial chemoembolization) wi...